|
Company data displayed is for sample purposes only and may not reflect the most current information available on Emerging Markets Information Service (EMIS).
Taisho Pharmaceutical Indonesia Tbk, PT
Main Activities: Chemical Manufacturing
 |
Please check the full coverage of information what EMIS can offer you. | SEE SAMPLE |
Company Information |
|
Full name Taisho Pharmaceutical Indonesia Tbk, PT Headquarters 10/F Wisma Tamara Jln Jend Sudirman Kav 24; Jakarta; Jakarta; 12920 |
Status: Listed Legal Form: Public Limited Company Operational Status: Operational ISIN CODE : ID1000070006 Financial Auditors: Tanudiredja, Wibisana & Rekan (2011) Incorporation Date: July 8, 1970 Total Employees: 114 Tel: (62 21) 5206727 |
|
Company Description |
| PT Taisho Pharmeceutical Indonesia Tbk, formerly PT Bristol-Myers Squibb Indonesia Tbk (SQBI) is engaged to develop, register, process, produce and sell chemical, pharmaceutical and health care products. The company commenced commercial operations in 1972 and was listed on Jakarta Stock Exchange on March 29, 1983. PT Tasiho Pharmaceutical Indonesia Tbk (SQBI) was established on July 08, 1970 and formarly named it with PT Bristol-Myers Squibb Indonesia. The head office is located in Jakarta, while | ||
|
||
Company Analysis |
| According to the Consolidated - Non-Audited financial statement for the first three cumulated quarters of 2012, total net operating revenues increased with 9.64%, from IDR 269,201,331 thousands to IDR 295,149,872 thousands. Operating result decreased from IDR 135,131,328 thousands to IDR 132,254,416 thousands which means -2.13% change. The results of the period increased 2.08% reaching IDR 101,992,168 thousands at the end of the period against IDR 99,913,992 thousands last year. Return on equity (Net income/Total equity) went from 35.39% to 34.92%, the Return On Asset (Net income / Total Asset) went from 29.32% to 29.15% and the Net Profit Margin (Net Income/Net Sales) went from 37.11% to 34.56% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 19.78% compared to 20.68% of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 5.28 to 5.59 when compared to the previous year. |
Key Executives |
|
|||||
|
|||||
|
|||||
|
|||||
Companies with Similar Main Activities |
FULL COMPANY PROFILE
|
|
2012 Y (cons) |
2012 Q3C (cons) |
|
 | ||
| Audited | Non-Audited | |
| ||
| WVB Company Financials | WVB Company Financials | |
| ||
| Unit | Thousands | Thousands |
| ||
Balance Sheet
| ||
Total Assets |
397,144,448 |
349,881,472 |
| ||
Current Assets |
307,406,496 |
261,374,368 |
| ||
Total Liabilities |
71,785,432 |
57,778,884 |
| ||
Shareholders Equity |
325,359,040 |
292,102,592 |
| ||
Current Liabilities |
63,322,304 |
46,774,984 |
| ||
| * All the accounts are in IDR. | ||
Income Statement
| ||
Total Operating Revenue |
392,843,169 |
295,149,872 |
| ||
Operational Profit (Loss) |
175,901,904 |
132,254,416 |
| ||
Net Profit (Loss) |
135,248,608 |
101,992,168 |
| ||
| * All the accounts are in IDR. | ||
Ratios
| Profitability Ratios | ||
| ||
Return on Assets (ROA) |
34.06% |
29.15% |
| ||
Annualised Return on Assets (ROA) |
34.06% |
38.87% |
| ||
Return on Equity (ROE) |
41.57% |
34.92% |
| ||
Annualised Return on Equity (ROE) |
41.57% |
46.56% |
| ||
Return on Sales (ROS) |
34.9% |
34.7% |
| ||
Return on Capital |
41.57% |
34.92% |
| ||
Gross Profit Margin |
62.84% |
62.18% |
| ||
Operating Profit Margin |
47.15% |
47.37% |
| Efficiency Ratios | ||
| ||
Accounts Receivable Turnover |
4.09x |
3.64x |
| ||
Inventory Turnover |
4.08x |
4.13x |
| ||
Current asset turnover |
1.26x |
1.12x |
| ||
Fixed-asset turnover |
4.32x |
3.32x |
| ||
Asset Turnover |
0.98x |
0.84x |
| Valuation figures and ratios | ||
| ||
Earning Before Interests and Taxes (EBIT) |
176,764,957 |
132,254,412 |
| ||
EBITDA |
188,018,689 |
140,439,540 |
| ||
Enterprise value |
2,135,682,273 |
2,153,530,512 |
| ||
Enterprise Value / EBITDA |
11.36 |
15.33 |
| ||
Bookvalue (BV) |
393,141,807 |
349,881,472 |
| ||
Net Cash |
108,096,064 |
102,792,504 |
| Liquidity Ratios | ||
| ||
Current Ratio |
485.46% |
558.79% |
| ||
Quick ratio |
429.67% |
501.29% |
| ||
Doom's day ratio |
270.71% |
319.76% |
| Leverage Ratios | ||
| ||
Leverage ratio |
122.06% |
119.78% |
| ||
Debt to equity |
22.06% |
19.78% |
| ||
Debt to total assets |
18.08% |
16.51% |
| ||
Long Term Debt to Capital |
45.25% |
51.8% |
| ||
Debt / Enterprise Value |
0.19% |
0% |
| Market ratios | ||
| ||
Market Capitalization/EBITDA |
12.25 |
16.40 |
| ||
Price/Book Ratio |
5.61 |
0.28 |
| ||
Market Cap / Net cash |
21.31 |
22.41 |
| Trend Ratios | ||
| ||
Revenue Trend |
113.38% |
109.71% |
| ||
Net Income Trend |
112.65% |
102.08% |
| ||
Operating Income Trend |
109.06% |
97.87% |
| ||
 |